A woman who is considering giving up on her hair loss journey after trying minoxidil and spironolactone, but other posters offer words of encouragement and suggest the use of wigs.
The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
The conversation discusses the appearance of hair transplants immediately after surgery, noting that scars will be covered as hair grows. The original poster underwent both FUT and FUE procedures.
Regrowing hairline without the use of Minoxidil or Finasteride, and instead using mechanical stimulation such as Derma Roller, Nizoral, Zinc Pyrithione, Scalp Massage, Scalp Exercise, Fish Oil and other topical solutions. It is cautioned that there are risks associated with not using medically-prescribed treatments, but it is suggested to consider mechanical stimulation in addition to those prescribed treatments.
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.